What question did this study set out to answer?

To review the epidemiology, diagnostic hallmarks, underlying cellular mechanisms, and evolving management approaches for minimal change disease across pediatric and adult populations.

December 9, 2016Clinical Journal of the American Society of NephrologyOpen Access

Minimal Change Disease

View Full Paper

Ask AI

Bookmark

Authors

MVMarina VivarelliBambino Gesù Children's Hospital LMLaura MassellaBambino Gesù Children's Hospital BRBarbara RuggieroUniversità Cattolica del Sacro Cuore

Discussion

Member takes

Implication

Clinical review demonstrates high steroid responsiveness alongside frequent relapses in minimal change disease, highlighting targeted therapies like anti-CD20 antibodies for long-term remission.

Key Points

To review the epidemiology, diagnostic hallmarks, underlying cellular mechanisms, and evolving management approaches for minimal change disease across pediatric and adult populations.
Evaluation of clinical presentation and diagnostic criteria, including the role of empirical steroid therapy versus renal biopsy.
Synthesis of histopathologic features across light and electron microscopy alongside proposed immunological and podocyte injury mechanisms.
Assessment of therapeutic outcomes associated with first-line corticosteroids, steroid-sparing regimens, and emerging biologic therapies.
Minimal change disease accounts for 70% to 90% of idiopathic nephrotic syndrome in children older than 1 year and approximately 15% in adults.
Light microscopy shows no visible abnormalities, while electron microscopy reveals diffuse effacement of podocyte foot processes driven by immune dysregulation.
Initial treatment with oral prednisone yields high remission rates, but frequent relapses occur, with anti-CD20 antibodies demonstrating efficacy for durable, treatment-free remission.

Cite This Study

Vivarelli et al. (2016) studied this question.

synapsesocial.com/papers/69def6987702a00918b0d445 https://doi.org/10.2215/cjn.05000516

View Full Paper

Ask AI

Bookmark

Implication

Clinical review demonstrates high steroid responsiveness alongside frequent relapses in minimal change disease, highlighting targeted therapies like anti-CD20 antibodies for long-term remission.